Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924261 | 0.81 | APOBEC3G (0.50) | APOBEC3GHSD11B1KMT2ACA1CA2 | |
| SCHEMBL11034530 | 0.81 | APOBEC3G (0.50) | APOBEC3GHSD11B1KMT2ACA1CA2 | |
| SCHEMBL8356839 | 0.80 | ALDH1A1 (0.50) | KMT2ACA1CA2CA12CA3 | |
| SCHEMBL8579922 | 0.79 | APOBEC3G (0.48) | APOBEC3GHSD11B1KMT2ACA1CA2 | |
| SCHEMBL3069669 | 0.79 | APOBEC3G (0.48) | APOBEC3GHSD11B1KMT2ACA1CA2 | |
| SCHEMBL15524946 | 0.78 | APOBEC3G (0.47) | APOBEC3GHSD11B1KMT2ACA1CA2 | |
| SCHEMBL27540835 | 0.78 | HSD11B1 (0.65) | APOBEC3GHSD11B1KMT2ACA12CA9 | |
| SCHEMBL174224 | 0.76 | KMT2A (0.62) | APOBEC3GHSD11B1KMT2ACA12CA9 | |
| SCHEMBL30244490 | 0.76 | APOBEC3G (0.45) | APOBEC3GHSD11B1KMT2ACA1CA2 | |
| SCHEMBL8645410 | 0.75 | APOBEC3G (0.44) | APOBEC3GHSD11B1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4733268-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| EP-1117409-B1 | BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-BLOCKERS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | AVENTIS PHARMA GMBH (DE) | 2005-01-26 | — | — | EP | claimed |
| EP-1401419-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | claimed |
| WO-2003000244-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-03 | — | — | WO | claimed |
| US-6414030-B1 | 1-((5-(2-(5-TERT-BUTYL-2-METHOXYBENZAMIDO)ETHYL)-2-METHOXYPHEN YL)-SULFONYL)-3-METHYLTHIOUREA AND PROPANOLOL FOR EXAMPLE | AVENTIS PHARMA DEUTSCHLAND, GMBH (DE) | 2002-07-02 | — | — | US | claimed |
| US-20020082300-A1 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | US | claimed |
| EP-1117409-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | Aventis Pharma Deutschland GmbH (DE) | 2001-07-25 | — | — | EP | claimed |
| WO-2000015204-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-03-23 | — | — | WO | claimed |
| JP-8245555-A | — | — | None | — | — | JP | disclosed |
| JP-7206807-A | — | — | None | — | — | JP | disclosed |
| JP-8245554-A | — | — | None | — | — | JP | disclosed |
| JP-8245553-A | — | — | None | — | — | JP | disclosed |
| EP-1117409-B1 | BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-BLOCKERS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | AVENTIS PHARMA GMBH (DE) | 2005-01-26 | — | — | EP | disclosed |
| EP-1401419-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| JP-H07206807-A | SUBSTITUTED BENZENESULFONYLUREA AND-THIOUREA, PREPARATION THEREOF AND USE OF PHARMACEUTICAL PREPARATION BASED ON THE SAME | HOECHST AG | 1995-08-08 | — | — | JP | disclosed |
| US-4282239-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-04 | — | — | US | disclosed |
| US-4025519-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-05-24 | — | — | US | disclosed |
| US-3962244-A | LOWERING OF BLOOD-SUGAR LEVELS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
| US-3939269-A | Benzenesulfon YL-semicarbazides for lowering blood sugar levels | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
| US-3932658-A | Composition and method for lower blood sugar containing N-[4-(β-<2-methoxy-5-chloro-benzamido>-ethyl)-benzenesulfonyl]-N'-cyclopentyl-urea | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082300-A1 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | UTS2R, TST, SIGMAR1 | APOBEC3G 4235/4885HSD11B1 3801/4885KMT2A 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.